Iovance Biotherapeutics (IOVA) Short-term Investments (2010 - 2026)

Iovance Biotherapeutics (IOVA) has reported Short-term Investments for 14 consecutive years, with $116.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Short-term Investments fell 37.82% year-over-year to $116.9 million; the TTM figure through Mar 2026 stood at $116.9 million (down 37.82% YoY), while the FY2025 annual figure was $133.9 million, down 35.65% from the prior year.
• Short-term Investments fell to $116.9 million in Q1 2026 per IOVA's latest filing, from $133.9 million in the prior quarter.
• Across five years, Short-term Investments topped out at $389.8 million in Q1 2022 and bottomed at $20.9 million in Q2 2023.
• Historically, Short-term Investments has averaged $182.1 million across 5 years, with a median of $168.7 million in 2025.
• Annual changes were most pronounced in 2023 — Short-term Investments plunged 93.39% — and 2024, when it soared 168.1%.
• Iovance Biotherapeutics' Short-term Investments stood at $240.1 million in 2022, then plunged by 31.29% to $165.0 million in 2023, then rose by 26.13% to $208.1 million in 2024, then slumped by 35.65% to $133.9 million in 2025, then retreated by 12.67% to $116.9 million in 2026.
• Business Quant data shows IOVA's Short-term Investments at $116.9 million in Q1 2026, $133.9 million in Q4 2025, and $142.7 million in Q3 2025.